EZH1 antagonist | EZH1 inhibitor | EZH1 agonist |EZH1activator

Cat.No.	Product Name	Information	Product Use Citations
S7165	UNC1999	UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. This compound is a potent autophagy inducer. It specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.	Cell Stem Cell, 2025, S1934-5909(25)00041-4 Cell Rep, 2025, 44(5):115673 bioRxiv, 2025, 2025.05.22.655558
S7656	CPI-360	CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.	Mol Ther Oncolytics, 2022, 27:14-25 Cancer Res, 2018, 78(20):5731-5740
S7165	UNC1999	UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. This compound is a potent autophagy inducer. It specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.	Cell Stem Cell, 2025, S1934-5909(25)00041-4 Cell Rep, 2025, 44(5):115673 bioRxiv, 2025, 2025.05.22.655558
S7656	CPI-360	CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.	Mol Ther Oncolytics, 2022, 27:14-25 Cancer Res, 2018, 78(20):5731-5740